Data mining and analysis of the adverse events derived signals of 4 gadolinium-based contrast agents based on the US Food and drug administration adverse event reporting system

References

• Runge VM. Commentary on T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol. 2015;50:481–482. doi: 10.1097/RLI.0000000000000182
   PubMed Web of Science ®Google Scholar
• Li H, Sun J, Zhu H, et al. Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis. Wiley interdisciplinary reviews. Nanomed Nanobiotechnol. 2021;13(2):e1670. doi: 10.1002/wnan.1670
   Google Scholar
• Idée JM, Port M, Robic C, et al. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009;30(6):1249–1258. doi: 10.1002/jmri.21967
   PubMed Web of Science ®Google Scholar
• Nakamura R, Takanezawa Y, Ohshiro Y, et al. Effects of chemical forms of gadolinium on the spleen in mice after single intravenous administration. Biochem Biophys Rep. 2022;29:101217. doi: 10.1016/j.bbrep.2022.101217
   PubMedGoogle Scholar
• Li A, Wong CS, Wong MK, et al. Acute adverse reactions to magnetic resonance contrast media–gadolinium chelates. Br J Radiol. 2006;79:368–371. doi: 10.1259/bjr/88469693
   PubMed Web of Science ®Google Scholar
• Jordan RM, Mintz RD. Fatal reaction to gadopentetatedime glumine. ALR. 1995;164(3):743–744. doi: 10.2214/ajr.164.3.7863905
   Google Scholar
• Aran S, Shaqdan KW, Abujudeh HH. Adverse allergic reactions to linear Ionic gadolinium-based contrast agents: experience with 194, 400 injections. Clin Radiol. 2015;70:466–475. doi: 10.1016/j.crad.2014.12.011
   PubMed Web of Science ®Google Scholar
• Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270(3):834–841. doi: 10.1148/radiol.13131669
   PubMed Web of Science ®Google Scholar
• Adin ME, Kleinberq L, Vaidya D, et al. Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol. 2015;36(10):1859–1865. doi: 10.3174/ajnr.A4378
   PubMed Web of Science ®Google Scholar
• Luo K, Liu G, Zhang X, et al. Functional L-Lysine dendritic macromolecules as liver-imaging probes. Macromol biosci. 2009;9(12):1227–1236. doi: 10.1002/mabi.200900231
   PubMed Web of Science ®Google Scholar
• Schieda NB, van der Pol C, Walker D, et al. Adverse events to the gadolinium-based contrast agent Gadoxetic Acid: systematic review and meta-analysis. Radiology. 2020;297(3):565–572. doi: 10.1148/radiol.2020200073
   PubMed Web of Science ®Google Scholar
• Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received Gadopentetate Dimeglumine. Invest Radiol. 2009;44(3):135–139. doi: 10.1097/RLI.0b013e31819343ba
   PubMed Web of Science ®Google Scholar
• Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000–1001. doi: 10.1016/S0140-6736(00)02694-5
   PubMed Web of Science ®Google Scholar
• Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4):1104–1108. doi: 10.1093/ndt/gfk062
   PubMed Web of Science ®Google Scholar
• Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563–576. doi: 10.1111/j.1472-8206.2006.00447.x
   PubMed Web of Science ®Google Scholar
• Dewachter P, Laroche D, Mouton-Faivre C, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol. 2011;77:495–501. doi: 10.1016/j.ejrad.2009.09.019
   PubMed Web of Science ®Google Scholar
• Davenport MS, Dillman JR, Cohan RH, et al. Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology. 2013;266(3):773–782. doi: 10.1148/radiol.12120253
   PubMed Web of Science ®Google Scholar
• Zou Z, Zhang HL, Roditi GH, et al. Nephrogenic systemic fibrosis: review of 370 biopsyconfirmed cases. JACC Cardiovascal Imaging. 2011;4(11):1206–1216. doi: 10.1016/j.jcmg.2011.08.013
   PubMed Web of Science ®Google Scholar
• Zhou J, Wei Z, Xu B, et al. Pharmacovigilance of triazole antifungal agents: analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2022;15:1039867. doi: 10.3389/fphar.2022.1039867
   Google Scholar
• Shahid I, Joseph A, Lancelot E. Use of real-life safety data from international pharmacovigilance databases to assess the importance of symptoms associated with gadolinium exposure. Invest Radiol. 2022;57(10):664–673. doi: 10.1097/RLI.0000000000000880
   PubMed Web of Science ®Google Scholar
• Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–486. doi: 10.1002/pds.677
   PubMed Web of Science ®Google Scholar
• Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf: Int J Medi Toxicol Drug Exper. 2003;26(3):159–186. doi: 10.2165/00002018-200326030-00003
   PubMed Web of Science ®Google Scholar
• Chai S, Zhan JL, Zhao LM, et al. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS. Ther Adv Drug Saf. 2022;13:1–13. doi: 10.1177/20420986221143266
   Web of Science ®Google Scholar
• Semelka RC, Prybylski JP, Ramalho M. Influence of excess ligand on nephrogenic systemic fibrosis associated with nonionic, linear gadolinium-based contrast agents. Magn Reson Imaging. 2019;58:174–178. doi: 10.1016/j.mri.2018.11.015
   PubMed Web of Science ®Google Scholar
• Moreno-Romero JA, Segura S, Mascaró JM Jr, et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol. 2007;157(4):783–787. doi: 10.1111/j.1365-2133.2007.08067.x
   PubMed Web of Science ®Google Scholar
• Todd DJ, Kay J. Gadolinium-induced fibrosis. Annu Rev Med. 2016;67:273–291. doi: 10.1146/annurev-med-063014-124936
   PubMed Web of Science ®Google Scholar
• Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol. 2016;311:F1–F11. doi: 10.1152/ajprenal.00166.2016
   PubMed Web of Science ®Google Scholar
• Mathur M, Jones JR, Weinreb JC. Gadolinium deposition and nephrogenic systemic fibrosis: a Radiologist’s primer. Radiographics. 2020;40(1):153–162. doi: 10.1148/rg.2020190110
   PubMed Web of Science ®Google Scholar
• Fraum TJ, Ludwig DR, Bashir MR, et al. Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging. 2017;46(2):338–353. doi: 10.1002/jmri.25625
   PubMed Web of Science ®Google Scholar
• Steger-Hartmann T, Hofmeister R, Ernst R, et al. A review of preclinical safety data for magnevist (Gadopentetate Dimeglumine) in the context of nephrogenic systemic fibrosis. Invest Radiol. 2010;45:520–528. doi: 10.1097/rli.0b013e3181e960c9
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Treatment of urticaria: a clinical and mechanistic approach. Curr Opin Allergy Clin Immunol. 2019;19:387–392. doi: 10.1097/ACI.0000000000000538
   PubMed Web of Science ®Google Scholar
• Dillman JR, Ellis JH, Cohan RH, et al. Frequency and severity of acute allergic-like reactions to gadolinium-containing i.V. contrast media in children and adults. AJR Am J Roentgenol. 2007;189(6):1533–1538. doi: 10.2214/AJR.07.2554
   PubMed Web of Science ®Google Scholar
• Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011;196(2):W138–W143. doi: 10.2214/AJR.10.4885
   PubMed Web of Science ®Google Scholar
• Murphy KPJ, Szopinski KT, Cohan RH, et al. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship directors. Acad Radiol. 1999;6(11):656–664. doi: 10.1016/S1076-6332(99)80114-7
   PubMed Web of Science ®Google Scholar
• Nelson KL, Gifford LM, Lauber-Hauber C, et al. Clinical safety of gadopentetate dimeglumine. Radiology. 1995;196(2):439–443. doi: 10.1148/radiology.196.2.7617858
   PubMed Web of Science ®Google Scholar
• Ramalho J, Ramalho M. Gadolinium deposition and chronic toxicity. Magn Reson Imaging Clin N Am. 2017;25(4):765–778. doi: 10.1016/j.mric.2017.06.007
   PubMed Web of Science ®Google Scholar
• Quattrocchi CC, Van der Molen AJ. Gadolinium retention in the body and brain: is it time for an international joint research effort? Radiology. 2017;282(1):12–16. doi: 10.1148/radiol.2016161626
   PubMed Web of Science ®Google Scholar
• McDonald JS, Hunt CH, Kolbe AB, et al. Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281945 injections. Radiology. 2019;292(3):620–627. doi: 10.1148/radiol.2019182834
   PubMed Web of Science ®Google Scholar
• Deng SX, Castelo M, Reel E, et al. High risk breast cancer screening is a Double Edged Sword: a qualitative study of patient perspectives on the Ontario high risk breast cancer screening program. Clin Breast Cancer. 2022;22(8):812–822. doi: 10.1016/j.clbc.2022.08.004
   PubMed Web of Science ®Google Scholar
• Wang LY, Liao LF, Lei CL, et al. Data mining for signal detection of adverse events for taxanes based on the Food and drug administration adverse drug events reporting system database. Expert Opin Drug Saf. 2023;22(9):833–839. doi: 10.1080/14740338.2023.2203487
   PubMed Web of Science ®Google Scholar
• Bower DV, Richter JK, Tengg-Kobligk HV, et al. Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent. Invest Radiol. 2019;54(8):453–463. doi: 10.1097/RLI.0000000000000567
   PubMed Web of Science ®Google Scholar